
After a Hot July for GM EV Sales, Is the Stock a Buy Now?
General Motors was the second-largest EV seller in the United States last year, just behind Tesla TSLA and managed to keep up the momentum through the first half of 2025. General Motors' EV sales in the last reported quarter more than doubled. Meanwhile, GM's closest peer, Ford F, witnessed more than a 30% drop in second-quarter EV sales year over year. EV giant Tesla recorded a 13.4% decline in deliveries in the three months ending June.
While General Motors' EV sales have been impressive, it will be interesting to watch if the company can sustain its sales growth amid policy shifts and U.S. President Trump's unfriendly stance on e-mobility. Let's take a closer look at the company's fundamentals to assess if General Motors is worth buying at the moment.
GM Maintains EPS Beat Streak in Q2 Despite Tariffs
General Motors' second-quarter 2025 earnings beat was its 12 th straight quarterly beat. Strong vehicle demand and stable vehicle pricing led to record first-half 2025 revenues of $91 billion. GMNA (General Motors North America) segment revenues were also a first-half record at roughly $77 billion.
The company was hit with $1.1 billion in net tariffs in the last reported quarter, although EPS of $2.53 exceeded expectations by 6%. However, GM expects net tariff costs in the third quarter to be higher than in the second quarter. It stuck to its guidance of gross tariff impact of $4-$5 billion for the full year but expects to offset roughly 30% of that through strategic initiatives like cost cuts, stable pricing and production adjustments. GM reaffirmed its adjusted EBIT forecast for the full year between $10 billion and $12.5 billion.
Factors Favoring General Motors
In the first half of the year, GM's U.S. market share climbed to 17.3%, up 1.2 percentage points from the same period last year — a steady, positive trend. The company continues to expand its U.S. manufacturing footprint and domestic supply chain, while also investing heavily in battery, software, and autonomous vehicle innovation. Internationally, GM is making meaningful progress. In China, it's working closely with its joint venture partner to improve sales, streamline inventory and boost profitability.
The strong performance of its new energy vehicles is also boosting results. Chevrolet has emerged as the number two EV brand in the United States, thanks to the success of the Blazer EV and Equinox EV. Meanwhile, Cadillac became the fifth-largest EV brand in the last reported quarter. GM is also scaling its hands-free driving system, Super Cruise. The technology is on track to generate over $200 million in revenues in 2025, with expectations to more than double by 2026.
The company's investor-friendly moves also augur well. It completed a $2 billion accelerated share repurchase program in the second quarter of 2025, retiring 10 million more shares. This brings the total shares bought back under that program to 43 million. Notably, GM resumed open market buybacks in early July.
GM's Performance & Valuation
Over the past three months, shares of General Motors have risen 16%, outperforming the industry as well as Ford and Tesla, which gained 5% and 12%, respectively.
From a valuation standpoint, General Motors appears relatively undervalued. The stock trades at a forward price-to-sales (P/S) ratio of just 0.29, well below the industry's 2.64. GM also boasts a Value Score of A. In comparison, Tesla and Ford trade at a P/S ratio of 9.7 and 0.27, respectively
Why Buying GM Stock Isn't a Good Idea Now
While GM continues to make strides in EVs and innovation, near-term headwinds are worth noting. Fleet pricing has come under pressure due to rising competition, and this trend is expected to persist in the second half of the year. GM also flagged higher warranty costs, particularly for the L87 powertrain and early EV software issues, which will be a drag in 2025.
Capital spending remains high and can weigh on free cash flow. While the company expects 2025 capex to be in the range of $10–$11 billion, the figure is expected to rise slightly to $10–$12 billion in 2026 and 2027 as GM ramps up production and future model launches.
The Zacks Consensus Estimate for GM's 2025 EPS and sales implies a year-over-year decline of 11% and 4.3%, respectively.
Adjusted EBIT for the first half of the year came in at $6.5 billion. Based on full-year guidance, second-half earnings are expected to be about $1.75 billion lower at the midpoint of the outlook. This is essentially due to three reasons. First, tariffs will remain a burden. Second, the company expects lower wholesale volumes in North America. Lastly, increased spending to prepare for the rollout of next-gen full-size trucks and the expansion of U.S. EV capacity will also weigh on the results.
Additionally, EV profitability may take a hit from softening demand because of the phase-out of government incentives like the federal tax credit. Given these headwinds, this isn't the best time for new investors to jump in.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here
Only $1 to See All Zacks' Buys and Sells
We're not kidding.
Several years ago, we shocked our members by offering them 30-day access to all our picks for the total sum of only $1. No obligation to spend another cent. Thousands have taken advantage of this opportunity.
Thousands did not - they thought there must be a catch. Yes, we do have a reason. We want you to get acquainted with our portfolio services like Surprise Trader, Stocks Under $10, Technology Innovators, and more, that closed 256 positions with double- and triple-digit gains in 2024 alone.
See Stocks Now >>
Ford Motor Company (F): Free Stock Analysis Report
Tesla, Inc. (TSLA): Free Stock Analysis Report
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Globe and Mail
7 minutes ago
- Globe and Mail
PERFORMANT HEALTHCARE INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Performant Healthcare, Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Performant Healthcare, Inc. (NasdaqGS: PHLT) to Machinify. Under the terms of the proposed transaction, shareholders of Performant will receive $7.75 in cash for each share of Performant that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit


Globe and Mail
7 minutes ago
- Globe and Mail
STAR EQUITY INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Star Equity Holdings, Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed sale of Star Equity Holdings, Inc. (NasdaqGM: STRR) to Hudson Global, Inc. (NasdaqGS: HSON). Under the terms of the proposed transaction, upon completion Star shareholders will own approximately 21% of the combined company. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit


Globe and Mail
7 minutes ago
- Globe and Mail
TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc.
Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC ('KSF') are investigating the proposed merger of Titan Pharmaceuticals, Inc. (the 'Company') (NasdaqCM: TTNP) and KE Sdn. Bhd. Under the terms of the proposed transaction, shareholders of Titan are expected to own approximately 13.3% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are adequate, or whether the merger is fair to the Company's shareholders. If you would like to discuss your legal rights regarding the proposed transaction, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn ( toll free at any time at 855-768-1857, or visit to learn more. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit